Conexeu Sciences Inc. (CNXU) News
Follow Conexeu Sciences Inc. (CNXU) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 15 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Conexeu Sciences Announces $5 Million Private Placement
The $5 million private placement is led by existing shareholders, management and directors.
EQUITY | Oct 15, 2026, 08:38 PM UTC
M
Conexeu Sciences Shares Up on Tissue Restoration Platform Progress
Shares of Conexeu Sciences gained 11% to $3.45 following company reports of progress for its CXU tissue restoration platform.
EQUITY | Oct 06, 2026, 07:13 PM UTC
M
Conexeu Sciences reports widened net loss and cash shortfall
Conexeu Sciences said widening net losses and insufficient cash for 12 months without new financing reflect higher marketing, staffing and regulatory costs, while it launches a prepaid IR campaign and targets filing an F
EQUITY | Sep 21, 2026, 11:28 AM UTC
L
Conexeu Sciences Inc. 3Q 2026: Revenue $0 Net loss $(7.73M), EPS $(0.29) — 10-Q Summary
Conexeu Sciences Inc. reported third-quarter 2026 results showing no revenue and a wider net loss as the company scaled operations following its May 2026 Nasdaq listing. The company posted no revenue for the three months
EARNINGS | Sep 14, 2026, 09:03 PM UTC
H
CNXU: Net loss surged as operating costs rose post-Nasdaq listing, with urgent need for new financing
Net loss widened significantly year-over-year due to increased operating expenses following the Nasdaq listing, with cash resources insufficient for the next twelve months absent new financing. Substantial investments in
EARNINGS | Sep 14, 2026, 08:38 PM UTC
L
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture
NEW YORK, Sept. 1, 2026 /CNW/ -- Equity Insider News Commentary - The global medical aesthetics market has quietly become one of the most durable growth stories in healthcare. Multiple market-research firms size it at ro
FX | Sep 01, 2026, 03:38 PM UTC
L
Conexeu Sciences schedules September and October 2026 conferences
Conexeu Sciences Inc. will participate in investor and industry conferences during September and October 2026, the company said.
EQUITY | Sep 01, 2026, 12:37 PM UTC
L
CNXU - Conexeu Sciences Sets September and October 2026 Conference Schedule
CNXU - Conexeu Sciences Sets September and October 2026 Conference Schedule
EQUITY | Sep 01, 2026, 12:30 PM UTC
L
CNXU - Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
CNXU - Conexeu Sciences Sees a New Category Forming in Medical Aesthetics as Research Turns to Regeneration
EQUITY | Aug 18, 2026, 12:30 PM UTC
H
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Liminatus Pharma (NASDAQ: LIMN ) stock increased by 40.9% to $0.16 during Thursday's pre-market session. The market value of their outstanding shares is at $5.8 million. Stablecoin Development (AMEX: SDEV ) stock
EARNINGS | Jul 02, 2026, 12:05 PM UTC
L
CNXU Opens R&D Facility
Conexeu Sciences opens Vancouver R&D facility to advance regenerative tissue platform
EQUITY | Jun 25, 2026, 12:31 PM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with different ratings
EQUITY | Jun 23, 2026, 10:55 AM UTC
M
CRDO: Credo Initiated
Credo Technology Group Holding Ltd initiated with Outperform rating and $325 price target by Evercore ISI Group analyst Mark Lipacis
EQUITY | Jun 22, 2026, 12:39 PM UTC
M
CNXU: HC Wainwright Initiates Buy
HC Wainwright & Co. initiates coverage on Conexeu Sciences with a buy rating and a price target of $20
EQUITY | Jun 22, 2026, 11:00 AM UTC
M
Banks Initiate Coverage
Multiple banks initiate coverage on various stocks with different ratings
EQUITY | Jun 22, 2026, 10:57 AM UTC